Date Added: 01/02/2017
Date Updated: 20/09/2017
EPICUP: epigenetic profiling to classify cancer of unknown primary
Specialties: Oncology & radiotherapy
Technology Type: Diagnostics
Stage of development: Nearly established
Stage of EAA: Identified
Description of the technology: Epigenetic technique that allows the classification of a group of cancers defined by the presence of metastatic disease with no identified primary tumour at presentation. The Epicub test is based on DNA methylation profiles (microarray DNA methylation signatures); it identifies the specific methylation profile of the tumour, assigning a primary origin to the unknown tumour sample. According to the company, Ferrer Hospital, Epicub has more than 90% coverage of the most frequent solid tumours and offers a very high overall accuracy. The company reports that it can be run in fresh frozen (FF) or formalin fixed and paraffin embedded (FFPE) procedures.
Patient indication: Patients diagnosed with cancer of unknown primary, CUP, (without the detection of the origin of the primary tumour with the usual techniques).